Skip to main content

Table 1 Baseline characteristics

From: Heart rate at discharge in patients with acute decompensated heart failure is a predictor of mortality

Patient characteristics all (n=78) HFrEF (n=58) HFmrEF (n=20) p value
Age (years) ± SD 69.4±13.3 68.2±13.5 72.9±12.2 0.176
Body mass index kg/m2 ± SD 28.0±5.6 27.9±5.5 28.1±6.0 0.867
Male / female sex (%/%) 78 / 22 79/21 75/25 0.687
Ejection fraction (%) ± SD 31.6±9.6 27.3±6.9 44.0±3.2 <0.001
Mean heart rate (bpm) ± SD 75±12 76±13 72±10 0.184
Systolic blood pressure (mmHg) 115.7±18.5 111.8±15.7 126.9±21.8 0.001
NYHA functional class
 III/IV (%/%) 66.7/33.3 66/34 70/30 0.714
Heart failure subtype
 ICM/DCM (%/%) 67.9 / 32.1 66/34 75/25 0.433
Devices
 Pacemaker (n/%) 17/21.8 15/26.0 2/10.0  
 ICD (n/%) 18/23.0 16/28.0 2/10.0  
 CRT (n/%) 2/2.6 2/3.4 0/0  
Comorbidities
 Atrial fibrillation (n/%) 34/43.6 23/39.7 11/55.0 0.142
 Diabetes mellitus (n/%) 33/42.3 24/41.4 9/45.0 0.926
 Arterial Hypertension (n/%) 59/75.6 43/74.1 16/80.0 0.598
 Hyperlipoproteinemia (n/%) 45/57.7 35/60.3 10/50 0.419
 Chronic renal failure (GFR≤ 60 ml/min) (n/%) 16/20.5 14/24.1 2/10 0.070
 Chronic obstructive pulmonary disease (n/%) 18/23.1 12/20.7 6/30.0 0.394
 Current smoker (n/%) 30/38.5 23/39.7 7/35.0 0.904
Laboratory values
 Haemoglobin (g/dl) ± SD 13.2±1.9 13.3±1.9 12.8±2.0 0.295
 Serum sodium (mmol/l) ± SD 138.9±4.1 139.0±4.1 138.7±4.6 0.734
 Cholesterine (mg/dl) ± SD 162.9±41.7 165.2±45.1 156.3±40.0 0.432
 Serum creatinine (mg/dl) ± SD 1.45±0.8 1.45±0.7 1.44±1.2 0.948
 Blood urea nitrogen (mg/dl) ± SD 72.7±41.2 73.0±41.0 71.8±42.7 0.909
NTpro-BNP (pg/ml) 6823±9824 7285±10024 352±0 0.516
Medication
 ACE inhibitor or ARB (%) 82.1 84.5 75 0.669
 Beta‐blocker (%) 91 91.4 90 0.813
 Aldosterone antagonist (%) 65.4 72.4 45 0.120
 Calcium antagonists (%) 10.3 3.4 30 0.030
 Diuretics (%) 91 96.6 75 0.117
 Digitalis glycosides (%) 28.2 29.3 25 0.200
 Amiodarone (%) 9 12.1 0 0.103
 Anticoagulant therapy (%) 33.3 31 40 0.220
 Antiplatelet therapy (%) 48.7 44.8 60 0.192
 Lipid lowering therapy (%) 50 50 50 0.762
 Xantine oxidase inihibitors (%) 21.8 24.1 15 0.520